Under construction – not a live service

Skip to content

Frontlight Research

Institution

Guy's Hospital

London, United KingdomhealthcareWebsite

70running trials
21closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

The site has not confirmed any trial yet.

Running trials

Not yet recruiting
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· Phase 3· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Source
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218· Phase 3· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Source
Recruiting
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360· Phase 2· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Source
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Source
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· Phase 2· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849· Phase 2· Source
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· Source
Recruiting
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268· Phase 3· Source
Active, not recruiting
WATER IV Prostate Cancer
NCT06651632· Source
Recruiting
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156· Phase 2· Source
Recruiting
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226· Phase 3· Source
Active, not recruiting
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686· Phase 2· Source
Active, not recruiting
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Source
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· Phase 2/3· Source
Recruiting
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805· Phase 1· Source
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· Phase 3· Source
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840· Phase 1· Source
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Source
Active, not recruiting
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733· Phase 3· Source
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· Phase 1/2· Source
Recruiting
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· Phase 3· Source
Recruiting
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
NCT05635162· Phase 2· Source
Active, not recruiting
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· Phase 3· Source
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Source
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· Phase 3· Source
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Source
Recruiting
HTL0039732 in Participants With Advanced Solid Tumours
NCT05944237· Phase 1/2· Source
Active, not recruiting
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· Phase 3· Source
Active, not recruiting
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799· Phase 2· Source
Recruiting
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure
NCT05568069· Source
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· Phase 3· Source
Active, not recruiting
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· Phase 3· Source
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Source
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Source
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Source
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· Phase 3· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Source
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Source
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Source
Active, not recruiting
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
NCT05421806· Source
Active, not recruiting
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685· Phase 2· Source
Active, not recruiting
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
NCT05570058· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· Source
Completed
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216· Phase 3· Source
Completed
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
NCT05185089· Phase 2· Source
Completed
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114· Phase 2· Source
Completed
Verapamil SR in Adults With Type 1 Diabetes
NCT04545151· Phase 2· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797· Phase 2/3· Source
Completed
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· Source
Completed
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
NCT04526106· Phase 1/2· Source
Withdrawn
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
NCT05867056· Phase 1· Source
Completed
Registry of Asthma Patients Initiating DUPIXENT®
NCT04287621· Source
Completed
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
NCT04199104· Phase 3· Source
Terminated
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
NCT03645928· Phase 2· Source
Completed
The Late Presenter Treatment Optimisation Study
NCT03696160· Phase 3· Source
Completed
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT03797326· Phase 2· Source
Completed
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
NCT03781934· Phase 1/2· Source
Completed
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110· Phase 3· Source
Completed
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664· Phase 3· Source
Completed
AFPᶜ³³²T in Advanced HCC
NCT03132792· Phase 1· Source
Completed
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
NCT02508467· Phase 1· Source
Completed
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer
NCT03048942· Phase 2· Source
Completed
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
NCT01726374· Phase 3· Source

Trial sites

Conditions

Diseases this institution publishes on or runs trials for.

Asthma46 works · 1 trials

Institution data: ROR 04r33pf22 (CC0-1.0)Updated 10 Nov 2026

Report an error

Under construction, not live – Guy's Hospital: trials and research groups – Frontlight Research